Skip to main content

OCD_Identification of Potential Plasma Biomarkers for Insulin Resistance Using Proteomics


EMSL Project ID
24104

Abstract

Insulin resistance is a prevalent medical condition that accompanies type 2 diabetes, obesity, hypertension, metabolic syndrome, and polycystic ovary disease. The insulin-resistant state has been referenced different ways, including the metabolic syndrome, syndrome X, and the dysmetabolic syndrome. Since insulin resistance may lead to diabetes mellitus and increased cardiovascular risk, an early diagnosis of that condition promises to significantly impact for the overall management of these disorders and the financial burden to the health care systems that is associated with those disorders.
All criteria include measurements of HDL cholesterol, triglycerides, blood pressure, glucose tolerance, and central obesity (using waist circumference or BMI). None of the diagnostic criteria include biochemical markers of inflammation or impaired fibrinolysis, although patients with insulin resistance have been shown to have significantly higher levels of several adipocytokines associated with accelerated atherogenesis and thrombosis, including C-reactive protein (CRP) and plasminogen activator inhibitor 1 (PAI-1), and lower levels of the protein adiponectin, which has been associated with cardiovascular risk.
Our goal in this project is to find and identify a biomarker or a set of biomarkers that is able to identify patients with insulin resistance by applying Battelle's proteomic approach to a prospective collection of plasma samples from patients with a combination of known risk factors for insulin resistance and prediabetes and enrolled in an IRB-approved clinical study.

Project Details

Project type
Exploratory Research
Start Date
2007-05-02
End Date
2008-05-04
Status
Closed

Team

Principal Investigator

Joel Pounds
Institution
Pacific Northwest National Laboratory

Team Members

Susan Varnum
Institution
Pacific Northwest National Laboratory